Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis patients


1Institute of General and Environmental Hygiene, University of Tübingen, Tübingen, Germany
2Cystic Fibrosis/Pulmonary Research and Treatment Center, The University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA
3Department of Medicine, University of Wisconsin, Madison Medical School, Madison, Wisconsin, USA
4Department of Pediatrics, Inselspital, University of Berne, Berne, Switzerland
5Service de Pédiatrie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
6Max-Planck-Institut für Entwicklungsbiologie, Tübingen, Germany
7Institute of Physical and Theoretical Chemistry, University of Tübingen, Tübingen, Germany

Address correspondence to: Richard C. Boucher, Cystic Fibrosis/Pulmonary Research and Treatment Center, 7011 Thurston-Bowles Building, CB 7248, The University of North Carolina, Chapel Hill, Chapel Hill, North Carolina 27599, USA. Phone: (919) 966-1077; Fax: (919) 966-7524; E-mail: rboucher@med.unc.edu. Dieter Worlitzsch, Robert Tarran, and Martina Ulrich contributed equally to this work. Richard C. Boucher and Gerd Döring contributed equally to this work as senior authors. Received for publication July 31, 2001, and accepted in revised form December 19, 2001.

Current theories of CF pathogenesis predict different predisposing “local environmental” conditions and sites of bacterial infection within CF airways. Here we show that, in CF patients with established lung disease, *Psuedomonas aeruginosa* was located within hypoxic mucopurulent masses in airway lumens. In vitro studies revealed that CF-specific increases in epithelial O₂ consumption, linked to increased airway surface liquid (ASL) volume absorption and mucus stasis, generated steep hypoxic gradients within thickened mucus on CF epithelial surfaces prior to infection. Motile *P. aeruginosa* deposited on CF airway surfaces penetrated into hypoxic mucus zones and responded to this environment with increased alginate production. With *P. aeruginosa* growth in oxygen restricted environments, local hypoxia was exacerbated and frank anaerobiosis, as detected in vivo, resulted. These studies indicate that novel therapies for CF include removal of hypoxic mucus plaques and antibiotics effective against *P. aeruginosa* adapted to anaerobic environments.


**Introduction**

Lung infections with *Pseudomonas aeruginosa* constitute the predominant disease phenotype in cystic fibrosis (CF) patients (1). Despite a vigorous and rapid influx of functional peripheral blood neutrophils into infected CF airways (2) accompanied by the production of high titers of specific Ab’s, *P. aeruginosa* infections become chronic (3), airways are destroyed, and lung function declines.

Several hypotheses have been offered to explain the failure of mucosal defense and the high prevalence of *P. aeruginosa* in the CF lung. Most hypotheses have focused on bacterial infection of CF airway epithelia, mediated by an increased binding of *P. aeruginosa* to the surfaces of CF airway epithelial cells (4, 5) impaired internalization and killing of *P. aeruginosa* by CF airway epithelia due to the absence of cystic fibrosis transmembrane conductance regulator (CFTR) at the apical surface (6), or “high-salt”–mediated defensin inactivation (7). In contrast, the reduced airway surface liquid (ASL) volume (impaired mucus clearance) hypothesis predicts infection by *P. aeruginosa* and other pathogens of stationary mucus adherent to airway surfaces.

As an approach to distinguish among these hypotheses, we sought to identify the site of *P. aeruginosa* infection in freshly excised CF airways, differentiating between the intraluminal (mucus) and epithelial surface compartments. Based on our observations that *P. aeruginosa* resided in the intraluminal contents of the CF lung, most hypotheses have focused on bacterial infection of CF airway epithelia, mediated by an increased binding of *P. aeruginosa* to the surfaces of CF airway epithelial cells (4, 5) impaired internalization and killing of *P. aeruginosa* by CF airway epithelia due to the absence of cystic fibrosis transmembrane conductance regulator (CFTR) at the apical surface (6), or “high-salt”–mediated defensin inactivation (7). In contrast, the reduced air-
hypoxygenation, e.g., increased alginate production, may favor its persistence in the CF lung.

Methods

Study subjects: normal, CF, and disease controls. Lungs from seven CF patients chronically infected with *P. aeruginosa* were obtained for morphometric analyses after lung transplantation (five males and two females, mean age 29.5 years; Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA) or after lobectomy (two females, mean age 8 years; Service de Pédiatrie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France). Nasal polyps from four CF patients (mean age 14.3 years; Ear, Nose and Throat Clinic, Klinikum Ludwigshafen, Germany), and from four non-CF individuals (mean age 46.5 years; Ear, Nose and Throat Clinic, University of Tübingen, Germany) were used for spheroid cell cultures. Cells for planar cell cultures were obtained from seven normal lung transplant donors (four males, three females, mean age 42 ± 6 years), eight CF lung transplant recipients (four males, three females, mean age 34 ± 3 years), and two primary ciliary dyskinesia (PCD) lung transplant donors (four males, three females, mean age 42 ± 6 years), eight CF lung transplant recipients (four males, three females, mean age 34 ± 3 years), and two primary ciliary dyskinesia (PCD) lung transplant recipients (one male, one female, ages 15 and 50 years, respectively). For in vivo oxygen partial pressure (pO2) measurements, six CF patients (two males, four females, mean age 23.8 years; mean forced expiratory volume in one second, 55.7% predicted) were studied. Data were successfully obtained from three patients. Informed consent was obtained from all patients and/or parents, and all parts of the study were approved by the local ethical committees.

Bacterial strains. PAO1 (8) bacteria were grown for adhesion experiments in vitro overnight at 37°C in 5 ml Trypticase soy broth (TSB; Oxoid Ltd., Basingstoke, United Kingdom). A bacterial suspension (10–50 µl) of the overnight culture (OD600nm 0.05) was inoculated into 5 ml fresh TSB medium and the bacteria cultured until the OD600nm of 1.5 was reached. For confocal microscopy studies, the *P. aeruginosa* strain ATCC 27853 was used. For alginate measurements, 15 genetically different non-CF (environmental) strains of *P. aeruginosa* were analyzed for binding to the epithelium.

Adhesion of *P. aeruginosa* to mucus adherent to primary nasal epithelial spheroids. The spheroid cell culture system was used as described previously (9). To collect secreted mucus, spheroids were incubated in DMEM/Ham’s F12 medium (Life Technologies Inc., Heidelberg, Germany) depleted of antibiotics and antimycotics for 5 days, supernatant collected by centrifugation (225 g), and stored at −20°C until use.

Spheroids (8 weeks; four CF and four normal [NL]), suspended in DMEM/Ham’s F12 medium, were incubated with *P. aeruginosa* at a cell/bacteria ratio of 1:100 for 2 hours/37°C/5% CO2. In some experiments, mucus was removed from spheroids by prewashing with PBS. After incubation with *P. aeruginosa*, spheroids were washed using a cell strainer (Becton Dickinson, Heidelberg, Germany). Twenty to 30 spheroids per individual were analyzed for adherence of *P. aeruginosa* by scanning electron microscopy (9).

*P. aeruginosa* was incubated with spheroid supernatants containing mucus for 2 hours at 37°C/5% CO2. After washing, bacteria were fixed on coverslips, incubated with a mAb to human mucins, washed, incubated with a Cy3-conjugated goat anti-mouse IgG (DAKO Corp., Hamburg, Germany) for 40 minutes at 23°C, washed with water, and embedded in Permafluor (Sigma Chemical Co., St. Louis, Missouri, USA).

Fiberoptic bronchoscopy. Fiberoptic bronchoscopy was performed as described previously (2) with minor modifications. For in vivo pO2 measurements, a computerized Clark type oxygen probe (length: 65 cm; outer diameter: 2 mm; inner diameter: 0.4 mm; Licox pO2; GMS, Kiel, Germany) was placed into the tip of the bronchoscope and guided under video control into right upper lobes obstructed with mucopusulent material.

Planar, primary bronchial culture system. Human airway epithelial cells were obtained from freshly excised bronchi by protease digestion (10), seeded directly on 12-mm Transwell Co membranes (Corning-Costar Corp., Cambridge, Massachusetts, USA) in modified bronchial epithelial growth medium under air-liquid interface conditions and studied when fully differentiated (2–5 weeks; transepithelial resistance of ≥ 350 Ω cm2).

Measurement of ASL pO2—planar bronchial cultures. O2 microelectrodes were purchased from Diamond General Development Corp. (Ann Arbor, Michigan, USA). The O2 microelectrode and 3 M KCl reference electrode were advanced into ASL with micromanipulators as described previously (11).

Confocal microscopy measurements of ASL/*P. aeruginosa*. PBS (30 µl) containing 2 mg/ml Texas Red-dextran (10
kDa; Molecular Probes Inc., Eugene, Oregon, USA) was added to CF cultures 2–48 hours before the addition of bacteria or fluorescent beads (1 µM; Molecular Probes Inc.) as described previously (12). For all studies, perfluorocarbon (FC-77, 3M Co., St. Paul, Minnesota, USA) was added to the mucus surface to prevent ASL evaporation.

*P. aeruginosa* bacteria were suspended in 3 ml PBS (OD<sub>470</sub> of 0.15 [~10<sup>6</sup> CFU/ml]) and incubated with 5 µM SYTO 13 (Molecular Probes Inc.) for 1 hour at 37°C. The bacterial suspension was washed once in PBS, centrifuged, and the pellet resuspended in PBS (100 µl).

**Bacterial growth and production of alginate by *P. aeruginosa* in aerobic and anaerobic culture conditions.** To determine whether *P. aeruginosa* is able to grow in freshly harvested ASL from CF and NL well-differentiated cultures (11) under aerobic and anaerobic (anaerobic chamber from Coy Laboratory Products, Gross Lake, Michigan, USA) conditions, a small number of bacteria (~100–200 CFU/0.5 µl) of PAO1 or the environmental *P. aeruginosa* strain (ATCC 700829) was added to 30 µl of ASL in parallel in two titer plates. For these experiments, the bacteria were grown on sheep blood agar overnight, suspended in PBS, with this suspension adjusted to an OD<sub>600</sub> of 0.15, diluted 1:100 in PBS, and starved for 2 hours before addition to ASL. Titer plates were incubated aerobically and anaerobically for 72 hours at 37°C. To determine the number of bacteria in ASL, samples were serially diluted and plated onto agar.

We next measured the alginate mass/bacterial protein mass under aerobic and anaerobic conditions, using anaerobic jars and Anaerocult A (Merck KGaA, Darmstadt, Germany), with strain PAO1 and 15 environmental *P. aeruginosa* strains grown on *Pseudomonas* isolation agar (PIA). After 4 days of growth, the bacteria were rinsed with water from the plates and the alginate was measured by the carbazole assay (13). Uronic acids were quantified using a standard curve of alginate purified from *Macrocystis pyrifera* (Sigma Chemical Co.), followed by the BCA protein assay to estimate bacterial protein mass (Pierce Chemical Co., Rockford, Illinois, USA). In parallel, we visualized *P. aeruginosa* alginate by immunostaining PAO1, grown on Columbia sheep blood agar and fixed on slides, with rabbit antisera specific for *P. aeruginosa* alginate followed by Cy3-labeled goat anti-rabbit IgG (Dianova).

Finally, we examined the role of nitrate as a terminal electron acceptor in alginate production under aerobic versus anaerobic conditions. PAO1 was grown on PIA agar plates (63 µM nitrate without added nitrate) to which a range of KNO<sub>3</sub> was added (10 µM–100 mM), and after 4 days of growth, alginate and bacterial protein was quantitated as above.

**Measurements of ASL total nitrate concentration.** Total nitrate (nitrite/nitrate) concentrations in CF and NL ASL (each CF/NL sample was obtained from pooled ASL collections from cultures derived from ten or more different subjects) were measured in 10 µl aliquots using a Nitric Oxide Analyzer (Sievers Model 280b, Ionics Instrument Business Group, Boulder, Colorado, USA).

**Bacteria and in vitro measurements of pO<sub>2</sub>**. Using the Licox oxygen probe, pO<sub>2</sub> was measured at 37°C in sus-

---

**Figure 1**

*P. aeruginosa* is localized in intraluminal material of freshly excised CF Airways and binds to mucus. (a) Thin section of an obstructed CF bronchus, stained with hematoxalin/eosin. Note the absence of *P. aeruginosa* on epithelial surface (black arrow) and presence of *P. aeruginosa* macrocolonies within intraluminal material (white arrows). Blue gap is an artifact due to fixation. (b) *P. aeruginosa* within macrocolonies in a lung section, stained with rabbit Ab’s against *P. aeruginosa*. Bars: a, 100 µm; b, 10 µm. (c) Percentage of bacteria detected at a distance of 2–5 µm or 5–17 µm from the epithelial surface of lungs from nine CF patients. Shrinkage artifacts were subtracted from calculated distances. (d) Scanning electron micrograph of mucus-coated spheroid derived from CF respiratory epithelium. *P. aeruginosa* (white arrow) were enmeshed in mucus (black arrows) following a 2-hour incubation. (e) Immunofluorescent staining of mucus (anti-mucin Ab) bound to *P. aeruginosa* strain PAO1 in vitro. (f) Spheroid with adherent mucus removed by prewash, then incubated with *P. aeruginosa* for 2 hours. Note the absence of bacteria on ciliated epithelial cell surfaces. Bars: d, 0.6 µm; e, 4 µm; f, 2.5 µm. Quantitative comparisons of PAO1 binding revealed higher binding to mucus-coated NES from normal subjects (21.3 ± 10.6 bacteria/NES) versus non-mucus-coated (washed) NES (7.1 ± 0.1 bacteria/NES) (α = 6; 3 normal subjects; P < 0.05). Importantly, these values were not different for CF NESs (26.4 ± 4.1 bacteria/NES for mucus-coated NESs; 7.7 ± 3.9 bacteria/NES for washed NESs).
pensions of PAO1 grown aerobically in TSB (Oxoid Ltd.). The pO$_2$ was also measured in heat-inactivated washed bacterial cultures at 10$^8$ CFU/ml.

Statistics. Unless otherwise stated, all data are presented as mean ± SEM. ANOVA (followed by the Tukey test) was used as appropriate. In the case of nonhomogeneity of variance, ANOVA followed by either Dunn’s multiple comparison test, the Mann-Whitney $U$ test, or the Wilcoxon signed rank test were used.

Results

$P$. aeruginosa is intraluminally located in CF airways. Analyses of CF lungs revealed evidence for growth of $P$. aeruginosa predominantly as spherical intraluminal colonies (Figure 1) (14). We have elected to refer to these spherical colonies as “macrocolonies,” because many are visible (>100 µm in diameter) to the naked eye. We used three separate techniques to test whether macrocolonies were localized to intraluminal mucus/mucopurulent material versus epithelial cell surfaces in CF lungs. First, immunolocalization in thin sections from nine different CF lungs revealed most bacteria (94.5%) were localized within the airway lumen 5–17 µm distant from the epithelial cell surface and the remainder in the zone 2–5 µm from the epithelial surface (Figure 1c). None were identified in contact with epithelial cells. Second, no $P$. aeruginosa bacteria were observed attached to airway epithelia in TEMs of bronchi from nine CF patients, containing a total length of 300 mm of bronchial surfaces. Third, scanning electron microscopy detected no bacteria on bronchial epithelia from two patients (total surface area examined: 116.1 mm$^2$).

$P$. aeruginosa binding to mucus versus airway epithelial cell membranes in vitro. We also tested the hypothesis that $P$. aeruginosa binds to mucus rather than airway epithelial cells in vitro. Nasal epithelial spheroids (NESs) spontaneously produce mucin, a fraction of which adheres to ciliated cells (9). Incubation of $P$. aeruginosa PAO1 with NESs revealed that the bacteria were enveloped by the mucus attached to NESs (Figure 1d). Mucin binding was also demonstrated by incubating $P$. aeruginosa with mucins secreted by NESs (Figure 1e). In contrast, washing NESs to remove adherent mucins greatly reduced $P$. aeruginosa binding (Figure 1f).

O$_2$ is depleted within Pseudomonas-infected intraluminal mucopurulent masses in vivo. The pO$_2$ in CF mucopurulent masses in vivo was measured by inserting an O$_2$ electrode directly into the right upper lobar bronchi of chronically infected CF patients (Figure 2a). When the probe was in the bronchial lumen, the pO$_2$ reached approximately 180 mmHg, a value consistent with the supplemental O$_2$ administered during bronchoscopy. Upon probe insertion into the mucopurulent material obstructing the lobar bronchus, the pO$_2$ declined rapidly to a mean value of 2.5 mmHg (Figure 2b).

In vitro analyses of the genesis of O$_2$ gradients in uninfected ASLs. The diffusion of O$_2$ through liquids is slow compared with air (15) so that the hypoxia measured within the mucopurulent luminal masses could reflect, in part, restricted O$_2$ diffusion through thickened intraluminal liquids. Although bacteria or neutrophils likely consume O$_2$ and contribute to the low pO$_2$ measured in...
in mucopurulent lumenal masses in vivo (see below), it is possible that the O₂ consumption of the underlying CF epithelium uniquely contributes to mucus O₂ gradients before infection.

To test the hypothesis that airway epithelial O₂ consumption generates O₂ gradients in liquid films that mimic in height mucus accumulated on CF airway surfaces (16), we measured O₂ gradients in NL and CF airway epithelia covered by an approximately 800-µm thick ASL (PBS). NL airway epithelia generated measurable O₂ gradients at 37°C in this layer (Figure 2c). Both NL and CF ASL O₂ gradients were abolished at 4°C, suggesting that the gradients indeed reflected epithelial O₂ consumption (Figure 2d).

Next, we asked whether the presence of mucins within ASL and mucus transport were important determinants of O₂ gradients under these thick film conditions. No differences in O₂ gradients were observed in CF cultures derived from patients with primary ciliary dyskinesia (PCD), a genetic disease of ciliary motility characterized by chronic airways infection (18). The pO₂ gradient was significantly steeper in CF cultures (Figure 2c). Both NL and CF ASL gradients were abolished at 4°C, suggesting that the gradients indeed reflected epithelial O₂ consumption (Figure 2d).

Do CF airway epithelia generate disease-specific steeper O₂ gradients within ASL? We measured the O₂ gradients in cultures derived from patients with primary ciliary dyskinesia (PCD), a genetic disease of ciliary motility characterized by chronic airways infection (18). The pO₂ gradients in PCD ASL resembled that of normal cultures and were shallower than CF ASL gradients (compare Figure 2, f and c). Thus, it appears that the ability to generate steep O₂ gradients within ASL reflected a unique feature of CF airway epithelia.

Will bacteria deposited on mucus surfaces penetrate to hypoxic zones in mucus layers? If bacteria contained within inhaled droplet aerosols deposit and remain on the surface of the mucus layer, then bacteria would be persistently exposed to normoxic environments. Conversely, if inhaled bacteria move (“swim”) into the mucus layer, they may face low pO₂. Two sets of experiments were designed to distinguish between these possibilities.

First, we examined the behavior of bacteria contained in small volumes (25 nl), designed to mimic aerosol droplets, deposited on the surface of CF airway epithelial cultures that exhibited rotational mucus transport. At the earliest time point measurable (3 minutes), motile P. aeruginosa penetrated into the mucus layer (Figure 3a). We next asked whether bacterial penetration into mucus reflected bacterial motility or mucus mixing in the vertical axis during rotational surface (horizontal) mucus transport (17). Fluorescently labeled beads deposited on the airway surface exhibited similar kinetics of penetration into the mucus layer, suggesting turbulent flow within the mucus layer accounted for penetration to hypoxic zones (Figure 3b).

Second, we tested whether motile P. aeruginosa could penetrate mucus masses adherent to CF airway surfaces. Within 15 minutes, P. aeruginosa had penetrated deep into the mucus (compare Figure 3, c with d). In contrast, fluorescent beads remained on the surface of the mucus plaque (compare Figure 3, e with f), suggesting that bacterial motility was required for P. aeruginosa penetration into hypoxic zones within stationary mucus masses.

Response of P. aeruginosa to a hypoxic environment. P. aeruginosa is an aerobic bacterium that will grow under anaerobic conditions if sufficient terminal electron acceptors are provided (19–21). Because it is not yet known what bacterial culture media best mimics human ASL (mucus), we tested for Pseudomonas growth under aerobic versus anaerobic conditions, using ASL harvested from CF and NL cultures. P. aeruginosa grew equally well in aerobic and anaerobic conditions (Figure 4a).

To test whether growth of Pseudomonas under anaerobic conditions in ASL was supported by NO₃⁻ as a ter-
Therefore, we measured typic features that allows it to evade host defenses.environments could induce patients (range 387–421 µM total nitrate concentrations were found between "stable" CF cultures, no differences in tracheal secretion total bronchi). Importantly, as we found in ASL from NL and representative in our cultures (third to sixth generation limiting concentrations of [NO3–] as a terminal electron acceptor, total nitrate concentration was measured and found to be not different in uninfected ASL from NL (20 µM) and CF (26 µM) cultures. These ASL total nitrate concentration values are substantially lower than those reported for airway secretions collected in vivo. For example, tracheal secretions from control subjects have been reported to contain 144–421 µM total nitrate (22, 23). The higher levels from tracheal secretions could reflect the fact that upper airways produce more NO than the lower airway regions (24, 25) that are representative in our cultures (third to sixth generation bronchi). Importantly, as we found in ASL from NL and CF cultures, no differences in tracheal secretion total nitrate concentrations were found between “stable” CF patients (range 387–421 µM) and controls (22, 23).

We next asked whether alginate production could, in part, reflect “stress” of an anaerobic environment with limiting concentrations of [NO3–] as a terminal electron acceptor. As shown in Figure 4d, the ratio of alginate to bacterial protein mass was highest at lower nitrate concentrations, including the 63 µM nitrate value of PIA (no added nitrate) that is most similar to values in ASL. Both immunofluorescence detection of alginate associated with the bacterial surface (Figure 4b; note thicker alginate coat in right panel) and quantitative measurement of alginate/bacterial protein mass (Figure 4c) demonstrated increased alginate production when PAO1 was grown under anaerobic conditions. A thicker alginate coat (−50%) was also observed for PAO1 grown in ASL under anaerobic versus aerobic conditions.

To test whether the behavior of PAO1 mimicked that of environmental strains that may infect CF mucus early in the course of the disease, alginate production by 15 nonmucoid P. aeruginosa environmental strains, genetically different by pulsed field gel electrophoretic analysis, was compared during growth in aerobic versus anaerobic environments. These strains routinely produced more alginate under anaerobic (0.191 ± 0.037 µg alginate per microgram of bacterial protein) versus aerobic (0.022 ± 0.004 µg alginate per microgram of bacterial protein) growth conditions.

We next tested whether alginate production could, in part, reflect “stress” of an anaerobic environment with limiting concentrations of [NO3–] as a terminal electron acceptor. As shown in Figure 4d, the ratio of alginate to bacterial protein mass was highest at lower nitrate concentrations, including the 63 µM nitrate value of PIA (no added nitrate) that is most similar to values in ASL.

Finally, we asked whether the introduction of bacteria as O2-consuming elements into mucus contributed to the magnitude of the O2 gradients observed in vivo (Figure 2). O2 tensions were reduced when P. aeruginosa growing in an open glass tube reached densities of approximately 5 × 106 to 5 × 107 CFU/ml (Figure 4e). At approximately 3 × 107 CFU/ml, virtually all O2 was consumed. Modeling of bacterial O2 consumption (Figure 4f) showed that anaerobic conditions are gen-

---

**Figure 4**

Growth and alginate production of *P. aeruginosa* under aerobic versus anaerobic conditions. (a) Growth of *P. aeruginosa* in NL or CF ASL under aerobic or anaerobic conditions. Two strains, PAO1 (black bars) and ATCC 700829 (gray bars), were inoculated (~100–200 bacteria, dashed line) in 30 µl NL or CF ASL and number of bacteria quantitated 72 hours later. The results presented are from a single representative experiment of three performed. The differences in the CFU/ml in the three experiments were less than 0.3 log 10. (b) Immunofluorescence detection of alginate production by PAO1 after aerobic (8 hours; left) or anaerobic (12 hours; right) conditions (magnification, ×1,000; bars, 10 µm). (c) Alginate production of PAO1 by the carbazole assay after growth under anaerobic (black bar) or aerobic (white bar) conditions for 4 days without added nitrate.

*P < 0.05. (d) Alginate production per microgram bacterial protein mass of PAO1 as a function of the added NO3– to PIA under aerobic (white bars) and anaerobic (black bars) conditions. (e) O2 tensions (filled triangles) as a function of time (hours). (f) Mathematical analysis of depths from air-mucus interface at which pO2 becomes zero for simulated mucus masses/plaques containing different concentrations of *P. aeruginosa* bacteria (colony-forming units per milliliter).
erated at very shallow depths (∼3 µm) in infected mucus masses when bacterial counts exceed $10^6$ CFU/ml. Thus, the cell-specific O$_2$ gradients within uninfected mucus accumulating on the CF airway epithelial surfaces will be exacerbated by the introduction of *P. aeruginosa* into mucus.

**Discussion**

Our studies initially focused on the pathogenesis of established CF airways infection and, taking clues from these studies, explored whether these variables could uniquely contribute to the early pathogenesis of *P. aeruginosa* infection in CF airways.

Morphometric analyses of freshly excised lungs by three techniques demonstrated that *P. aeruginosa* grows as macrocolonies in the airway intraluminal rather than the epithelial surface compartment (Figure 1, a–c). These findings contradict recent hypotheses emanating from in vitro model systems that focus on high-salt/defensin inactivation (26) or luminal epithelial cell binding (4), which predict bacterial infection of CF airway epithelial cells themselves (5, 6). However, our data are consistent with those from animal models that have demonstrated the adherence of *P. aeruginosa* to respiratory mucus (27–29), and three previous qualitative studies of CF postmortem lungs that identified *P. aeruginosa* in airway lumens rather than on airway epithelial cells (30–32). Furthermore, they are also consistent with our studies of NSEs that revealed *P. aeruginosa* preferentially bound to mucus rather than epithelial cell surfaces (Figure 1, d–f). A key extension of the in vivo characterization of CF airways infection is that *P. aeruginosa* occupies an intraluminal niche that is markedly hypoxic (Figure 2, a–b).

If the CF airways disease reflects infection of mucus, how is this process initiated and perpetuated? A sequence consistent with several aspects of the “low volume/reduced mucus clearance” hypothesis (10, 33) for CF pathogenesis is outlined in Figure 5. First, as compared with NL airway epithelial function (compare Figure 5a), data have been reported that CF airway epithelia excessively absorb Na$^+$ and Cl$^-$ (and water) from the lumen, deplete the periciliary liquid layer (PCL), and slow/abolish mucus clearance (Figure 5b) (10, 34, 35). Accelerated Na$^+$ absorption, which reflects the absence of CFTR’s normal inhibitory activity on ENaC (36), is fueled by an increased turnover rate of ATP-consuming Na$^+$-K$^+$-ATPase pumps (37, 38) leading to two- to threefold increases in CF airway epithelial O$_2$ consumption (39).

Second, persistent mucin secretion into stationary mucus generates plaques/plugs (16) (Figure 5c). The combination of thickened mucus and raised O$_2$ consumption by CF epithelia generated steep O$_2$ gradients within adherent mucus (Figure 2c). Importantly, the

![Figure 5](image-url)

Figure 5
Schematic model of the pathogenic events hypothesized to lead to chronic *P. aeruginosa* infection in airways of CF patients. (a) On normal airway epithelia, a thin mucus layer (light green) resides atop the PCL (clear). The presence of the low-viscosity PCL facilitates efficient mucociliary clearance (denoted by vector). A normal rate of epithelial O$_2$ consumption (QO$_2$; left) produces no O$_2$ gradients within this thin ASL (denoted by red bar). (b–f) CF airway epithelia. (b) Excessive CF volume depletion (denoted by vertical arrows) removes the PCL, mucus becomes adherent to epithelial surfaces, and mucus transport slows/stops (bidirectional vector). The raised O$_2$ consumption (left) associated with accelerated CF ion transport does not generate gradients in thin films of ASL. (c) Persistent mucus hypersecretion (denoted as mucus secretory gland/goblet cell units; dark green) with time increases the height of luminal mucus masses/plugs. The raised CF epithelial QO$_2$ generates steep hypoxic gradients (blue color in bar) in thickened mucus masses. (d) *P. aeruginosa* bacteria deposited on mucus surfaces penetrate actively and/or passively (due to mucus turbulence) into hypoxic zones within the mucus masses. (e) *P. aeruginosa* adapts to hypoxic niches within mucus masses with increased alginate formation and the creation of macrocolonies. (f) Macrocolonies resist secondary defenses, including neutrophils, setting the stage for chronic infection. The presence of increased macrocolony density and, to a lesser extent neutrophils, render the now mucopurulent mass hypoxic (blue bar).
stiff pO2 gradient in ASL/mucus was specific for CF epithelia because it was not reproduced in cultures from another genetic airways disease with an infectious phenotype, PCD (Figure 2f).

Third, bacteria deposited on thickened mucus can penetrate into hypoxic zones (Figure 5d). When the normal rotational mucus transport ceased due to excessive volume absorption, the vertical “currents” within transported mucus were abolished, but motile P. aeruginosa still penetrated thickened mucus (Figure 3, c and d). Note that environmental P. aeruginosa strains such as those that characterize early infection are motile and would likely penetrate mucus readily.

Fourth, P. aeruginosa can grow in hypoxic/anaerobic CF mucus (Figure 4a). In part, growth under anaerobic conditions may be supported by the terminal electron acceptor, nitrate (−20 µM), contained in ASL. Furthermore, we show that increased alginate production was a characteristic feature of PAO1 strains in response to hypoxia, particularly with growth in low concentrations of nitrate that mimic ASL (Figure 4, b–d), and this characteristic is also a feature of environmental P. aeruginosa strains. We speculate that the increased alginate formation may represent a stress response to hypoxia that is part of the process that forms biofilmlike macrocolonies, the predominant phenotype of P. aeruginosa in CF airways (3). Interestingly, Staphylococcus aureus also responds to the hypoxic environment of CF mucus with a switch from non-mucoid to a mucoid phenotype (40, 41).

Finally, the capacity of P. aeruginosa to proliferate in hypoxic mucus will generate fully hypoxic (anaerobic) conditions in patients with persistent CF airways infection (Figure 1, Figure 4, e and f, and Figure 5e). Hassett et al. reported that P. aeruginosa alginate production was maintained by anaerobic conditions (21). The reduced O2 tension in the mucopurulent intraluminal contents of CF airways may, therefore, be one variable contributing to the persistence of P. aeruginosa macrocolonies in CF airways. The consequences of the macrocolony growth state have been explored in detail and include resistance to antibiotics (42) and host phagocyte killing (Figure 5f) and (42, 43), all of which contribute to the persistence of P. aeruginosa infection and the chronic destructive airways disease characteristics of CF.

In summary, our data demonstrate that the P. aeruginosa infection of CF airways occurs within the luminal (mucus) rather than the epithelial cell surface compartment. Thus, we speculate that mucus clearance is a key feature of innate lung defense (44), and a fundamental defect leading to chronic CF lung infections is the failure to effectively clear mucus that contains bound bacteria from the lung (10). Hypoxic gradients exist within poorly cleared/adherent mucus, consequent to CF-specific increases in epithelial O2 consumption, and inhaled P. aeruginosa respond to hypoxic mucus with alginate production and macrocolony formation, which allows them to evade host defenses and produce a chronic destructive lung disease. These data lead us to conclude that therapeutic strategies to treat CF lung disease should include novel drugs designed to clear the lung of retained mucus plagues/plugs, which initiate and perpetuate CF lung disease, and antibiotics that effectively treat P. aeruginosa growing under hypoxic/anaerobic conditions.

Acknowledgments

The authors would like to thank Carol Basbaum for a gift of an mAb against human tracheobronchial mucins, Gerald Pier for a gift of rabbit antiserum specific for P. aeruginosa alginate, Hans-Peter Zemner and Gerd Münker for nasal polypl material, Heinz Schwarz for TEM, and Diana Walstad, Kim Burns, and Tracy Bartolotta for technical assistance. We also thank Marie Becker for harvesting ASL and Milan Hazucha for nitrate measurements. This study was partially supported by Förderverein für Mukoviszidosekranke Kinder, Jugendliche und Erwachsene der Region Ulm e.V., Deutsche Gesellschaft zur Bekämpfung der Mukoviszidose e.V., and the CF-Sellbshilfe Duisburg e.V., Germany.


